The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
Open accessAbstract
Preclinical studies suggest that treatment with neoadjuvant immune checkpoint blockade is associated with enhanced survival and antigen-specific T cell responses compared with adjuvant treatment1; however, optimal regimens have not been defined. Here we report results from a randomized phase 2 study of neoadjuvant nivolumab versus combined ipilimumab with nivolumab in 23 patients with high-risk resectable melanoma (NCT02519322). RECIST overall response rates (ORR), pathologic complete response rates (pCR), treatment-related adverse events (trAEs) and immune correlates of response were assessed. Treatment with combined ipilimumab and nivolumab yielded high response rates (RECIST ORR 73%, pCR 45%) but substantial toxicity (73% grade 3 trAEs), whereas treatment with nivolumab monotherapy yielded modest responses (ORR 25%, pCR 25%) and low toxicity (8% grade 3 trAEs). Immune correlates of response were identified, demonstrating higher lymphoid infiltrates in responders to both therapies and a more clonal and diverse T cell infiltrate in responders to nivolumab monotherapy. These results describe the feasibility of neoadjuvant immune checkpoint blockade in melanoma and emphasize the need for additional studies to optimize treatment regimens and to validate putative biomarkers. Neoadjuvant combination treatment with nivolumab and ipilimumab in patients with high-risk melanoma results in higher response rates than nivolumab monotherapy and warrants future optimization of dosing regimens to preserve efficacy while limiting toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“analyses of samples derived from patients with melanoma who received neoadjuvant ICIs112,113 have revealed the presence of the three primary patterns of T cell infiltration identified in solid tumours.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [113]
Experimental — accuracy not yet measuredIn the citing paper
“Studies in melanoma using higher dosages of ipilimumab reported enhanced immune infiltration in responding tumors17.”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [17]
In the citing paper
“Amaria and colleagues17 demonstrated that a more clonal T-cell repertoire at baseline correlated with response to neoadjuvant ICI therapy in patients with melanoma, with further expansion of the pre-existing high-frequency clones with treatment.”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [17]
In the citing paper
“Key roles of TGF-β1 in suppressing the adaptive immune system are apparent from the lymphoproliferative autoimmune phenotype of Tgfb1−/− mice197–199, and similar phenotypes following selective ablation of TGF-β signaling components within CD4+ and CD8+ T cells200.”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [198]
In the citing paper
“Clinical trials with ICT in the neoadjuvant setting have now demonstrated clinical benefit in multiple tumor types, including melanoma (173, 174), Merkel cell carcinoma (175), NSCLC (176), MMRdeficient colorectal cancer (177), urothelial carcinoma (21, 178), and breast cancer (179-181).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [173]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
A framework for variation discovery and genotyping using next-generation DNA sequencing data
DePristo, M. A., Banks, E., Poplin, R. E., Garimella, K. V., Maguire, J., Hartl, C., Philippakis, A., del Angel, G., Rivas, M. A., Hanna, M., et al. (2011) · Nature Genetics · doi:10.1038/ng.806 · Cited by 11,508
Edge, S. B., & Compton, C. C. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-0985-4 · Cited by 9,055
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Acute Abdomen: A Rare Case of Ruptured Hepatocellular Carcinoma
Gloor, S., Jensen, K. O., Breitenstein, S., Binkert, C. A., Angst, E., & Hetzer, F. H. (2017) · Case Reports in Gastroenterology · doi:10.1159/000463378 · Cited by 5,370
Research works printed but not linked: 1
- Edge, S. B. AJCC Cancer Staging Manual 7th edn (Springer, New York, 2010).
Cited by
Sorted by citations
Items 101–200 of 838
Dendritic Cells, the T-cell-inflamed Tumor Microenvironment, and Immunotherapy Treatment Response
Garris, C., & Luke, J. J. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1321 · Cited by 146
Cell‐Based Delivery Systems: Emerging Carriers for Immunotherapy
Li, Z., Wang, Y., Ding, Y., Repp, L., Kwon, G. S., & Hu, Q. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202100088 · Cited by 138
Toll-Like Receptor 9 Agonists in Cancer
Karapetyan, L., Luke, J. J., & Davar, D. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s247050 · Cited by 138
Verschoor, Y. L., van de Haar, J., van den Berg, J. G., van Sandick, J. W., Kodach, L. L., van Dieren, J. M., Balduzzi, S., Grootscholten, C., Ijsselsteijn, M. E., Veenhof, A. A. F. A., et al. (2024) · Nature Medicine · doi:10.1038/s41591-023-02758-x · Cited by 135
Clinical and translational attributes of immune-related adverse events
Suijkerbuijk, K. P. M., van Eijs, M. J. M., van Wijk, F., & Eggermont, A. M. M. (2024) · Nature Cancer · doi:10.1038/s43018-024-00730-3 · Cited by 136
Singla, N., Hutchinson, R. C., Ghandour, R. A., Freifeld, Y. N., Fang, D., Sagalowsky, A. I., Lotan, Y., Bagrodia, A., Margulis, V., Hammers, H. J., et al. (2020) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2020.02.029 · Cited by 127
Zhang, Y., Du, X., Liu, M., Tang, F., Zhang, P., Ai, C., Fields, J. K., Sundberg, E. J., Latinovic, O., Devenport, M., et al. (2019) · Cell Research · doi:10.1038/s41422-019-0184-1 · Cited by 123
Reardon, D. A., Kim, T. M., Frenel, J., Simonelli, M., Lopez, J. S., Subramaniam, D. S., Siu, L. L., Wang, H., Krishnan, S., Stein, K. F., et al. (2021) · Cancer · doi:10.1002/cncr.33378 · Cited by 127
Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment
Saab, S., Zalzale, H., Rahal, Z., Khalifeh, Y., Sinjab, A. F., & Kadara, H. N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00159 · Cited by 122
Changing Technologies of RNA Sequencing and Their Applications in Clinical Oncology
Wang, Y., Mashock, M. J., Tong, Z., Mu, X., Chen, H., Zhou, X., Zhang, H., Zhao, G., Liu, B., & Li, X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00447 · Cited by 123
PD-1 blockade therapy promotes infiltration of tumor-attacking exhausted T cell clonotypes
Nagasaki, J., Inozume, T., Sax, N., Ariyasu, R., Ishikawa, M., Yamashita, K., Kawazu, M., Ueno, T., Irie, T., Tanji, E., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110331 · Cited by 126
Tumor Vasculatures: A New Target for Cancer Immunotherapy
Liu, Z., Wang, Y., Huang, Y., Kim, B. Y. S., Shan, H., Wu, D., & Jiang, W. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.07.001 · Cited by 122
Wang, K., Coutifaris, P., Brocks, D., Wang, G., Azar, T., Solis, S., Nandi, A., Anderson, S., Han, N. A., Manne, S., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.08.007 · Cited by 127
Michielin, O. A., van Akkooi, A. C. J., Lorigan, P. C., Ascierto, P. A., Dummer, R., Robert, C., Arance, A. M., Blank, C. U., Chiarion‐Sileni, V., Donia, M., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.07.005 · Cited by 117
Self-citationWu, D., Li, Y., Xu, P., Fang, Q., Cao, F., Lin, H., Li, Y., Su, Y., Lu, L., Chen, L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46444-z · Cited by 124
Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome
Liu, J., O’Donnell, J. S., Yan, J., Madore, J., Allen, S. M., Smyth, M. J., & Teng, M. W. L. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1581530 · Cited by 112
Zugazagoitia, J., Gupta, S., Liu, Y., Fuhrman, K. A., Gettinger, S. N., Herbst, R. S., Schalper, K. A., & Rimm, D. L. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0175 · Cited by 116
Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma
Grossmann, K. F., Othus, M., Patel, S. P., Tarhini, A. A., Sondak, V. K., Knopp, M. V., Petrella, T. M., Truong, T.-G., Khushalani, N. I., Cohen, J. V., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1141 · Cited by 115
Self-citationEvolving impact of long-term survival results on metastatic melanoma treatment
Michielin, O. A., Atkins, M. B., Koon, H. B., Dummer, R., & Ascierto, P. A. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000948 · Cited by 119
Tumor microenvironment in head and neck squamous cell carcinoma: Functions and regulatory mechanisms
Wang, G., Zhang, M., Cheng, M., Wang, X., Li, K., Chen, J., Chen, Z., Chen, S., Chen, J., Xiong, G., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.03.009 · Cited by 113
Beechem, J. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9773-2_25 · Cited by 105
Lisi, L., Lacal, P. M., Martire, M., Navarra, P., & Graziani, G. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105997 · Cited by 106
Immunotherapy Goes Local: The Central Role of Lymph Nodes in Driving Tumor Infiltration and Efficacy
van Pul, K. M., Fransen, M. F., van de Ven, R., & de Gruijl, T. D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.643291 · Cited by 105
Hematological immune related adverse events after treatment with immune checkpoint inhibitors
Kramer, R., Zaremba, A., Moreira, A., Ugurel, S., Johnson, D. B., Hassel, J. C., Salzmann, M., Gesierich, A., Weppler, A. M., Spain, L. A., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.01.013 · Cited by 105
Immunotherapy for Non-melanoma Skin Cancer
Shalhout, S. Z., Emerick, K. S., Kaufman, H. L., & Miller, D. M. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01120-z · Cited by 108
Decalf, J., Albert, M. L., & Ziai, J. M. (2018) · The Journal of Pathology · doi:10.1002/path.5223 · Cited by 105
Current Progresses and Challenges of Immunotherapy in Triple-Negative Breast Cancer
Mediratta, K., El‐Sahli, S., D’Costa, V. M., & Wang, L. (2020) · Cancers · doi:10.3390/cancers12123529 · Cited by 102
Self-citationNeoadjuvant Checkpoint Immunotherapy and Melanoma: The Time Is Now
Long, G. V., Menzies, A. M., & Scolyer, R. A. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02575 · Cited by 105
Lai, A. Y., Sorrentino, J. A., Dragnev, K. H., Weiss, J., Owonikoko, T. K., Rytlewski, J. A., Hood, J. V. W., Zhao, Y., Malik, R. K., Strum, J. C., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000847 · Cited by 100
Bergholtz, H., Carter, J. M., Cesano, A., Cheang, M. C. U., Church, S., Divakar, P., Fuhrman, C. A., Goel, S., Gong, J., Guerriero, J. L., et al. (2021) · Cancers · doi:10.3390/cancers13174456 · Cited by 101
Self-citationNeoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma
Knochelmann, H. M., Horton, J. D., Liu, S., Armeson, K. E., Kaczmar, J. M., Wyatt, M. M., Richardson, M. S., Lomeli, S. H., Xiong, Y., Graboyes, E. M., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100426 · Cited by 102
Signaling pathways in brain tumors and therapeutic interventions
Li, S., Wang, C., Chen, J., Lan, Y., Zhang, W., Kang, Z., Zheng, Y., Zhang, R., Yu, J., & Li, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01260-z · Cited by 105
Chuntova, P., Chow, F. E., Watchmaker, P. B., Galvez, M., Heimberger, A. B., Newell, E. W., Diaz, A. A., DePinho, R. A., Li, M. O., Wherry, E. J., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa277 · Cited by 89
T follicular helper and B cell crosstalk in tertiary lymphoid structures and cancer immunotherapy
Garaud, S., Dieu‐Nosjean, M., & Willard-Gallo, K. E. (2022) · Nature Communications · doi:10.1038/s41467-022-29753-z · Cited by 98
Pu, N., Gao, S., Yin, H., Li, J.-A., Wu, W., Fang, Y., Zhang, L., Rong, Y., Xu, X., Wang, D., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.06.013 · Cited by 91
Characteristics of TCR Repertoire Associated With Successful Immune Checkpoint Therapy Responses
Kidman, J., Principe, N., Watson, M. W., Lassmann, T., Holt, R. A., Nowak, A. K., Lesterhuis, W. J., Lake, R., & Chee, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.587014 · Cited by 94
Presti, D., Dall’Olio, F. G., Besse, B., Ribeiro, J. M., Meglio, A. D., & Soldato, D. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103773 · Cited by 90
Cancer Immunotherapies: From Efficacy to Resistance Mechanisms – Not Only Checkpoint Matters
Wang, S., Xie, K., & Liu, T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.690112 · Cited by 90
Exploiting temporal aspects of cancer immunotherapy
Zemek, R. M., Anagnostou, V., da Silva, I. P., Long, G. V., & Lesterhuis, W. J. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00699-2 · Cited by 96
Neoadjuvant Immune Checkpoint Inhibitors Plus Chemotherapy in Early Breast Cancer
Villacampa, G. J., Navarro, V., Matikas, A., Ribeiro, J. M., Schettini, F., Tolosa, P., Martínez‐Sáez, O., Sánchez-Bayona, R., Ferrero-Cafiero, J. M., Salvador, F., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.3456 · Cited by 92
Werner, F., Wagner, C., Simon, M., Glatz, K., Mertz, K. D., Laubli, H. P., Griss, J., & Wagner, S. N. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.675146 · Cited by 88
de Rodas, M. L., Villalba-Esparza, M., Sanmamed, M. F., Chen, L., Rimm, D. L., & Schalper, K. A. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00984-x · Cited by 98
Reprograming the tumor immunologic microenvironment using neoadjuvant chemotherapy in osteosarcoma
Deng, C., Xu, Y., Fu, J., Zhu, X., Chen, H., Xu, H., Wang, G., Song, Y., Song, G., Lu, J., et al. (2020) · Cancer Science · doi:10.1111/cas.14398 · Cited by 82
Ballerini, M., Galié, S., Tyagi, P., Catozzi, C., Raji, H., Nabinejad, A., Macandog, A. D. G., Cordiale, A., Slivinschi, B. I., Kugiejko, K. K., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01318-z · Cited by 98
Self-citationZheng, L., Ding, D., Edil, B. H., Judkins, C., Durham, J. N., Thomas, D. L., Bever, K. M., Mo, G., Solt, S., Hoare, J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2974 · Cited by 82
IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma
Reijers, I. L. M., Rao, D., Versluis, J. M., Menzies, A. M., Dimitriadis, P., Wouters, M. W. J. M., Spillane, A. J., Klop, W. M. C., Broeks, A., Bosch, L. J. W., et al. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20221952 · Cited by 86
He, B., Johansson, A., Backhouse, J., Li, J., Lee, G., Hamzah, J., & Ganß, R. (2020) · Cell Reports · doi:10.1016/j.celrep.2019.12.013 · Cited by 81
Fidelle, M., Yonekura, S., Picard, M., Cogdill, A. P., Hollebecque, A., Roberti, M. P., & Zitvogel, L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.600886 · Cited by 87
Fujiwara, Y., Horita, N., Adib, E., Zhou, S., Nassar, A. H., Asad, Z. U. A., Cortellini, A., & Naqash, A. R. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00524-7 · Cited by 88
Seban, R., Moya‐Plana, A., Antonios, L., Yeh, R., Marabelle, A., Deutsch, É., Schwartz, L. H., Gómez, R. G. H., Saenger, Y. M., Robert, C., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04757-3 · Cited by 82
Ludford, K. T., Cohen, R., Svrcek, M., Foo, W. C., Colle, R., Parc, Y. R., Thomas, J. V., Morris, V. K., Kopetz, S., Chang, G. J., et al. (2020) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaa052 · Cited by 82
Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapies
Li, H., Zandberg, D. P., Kulkarni, A., Chiosea, S. I., Santos, P. M., Isett, B. R., Joy, M., Sica, G., Contrera, K. J., Tatsuoka, C. M., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.02.026 · Cited by 85
Newton, J. M., Hanoteau, A., Liu, H., Gaspero, A., Parikh, F., Gartrell, R. D., Hart, T. D., Laoui, D., Ginderachter, J. A. V., Dharmaraj, N., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0698-6 · Cited by 82
Ceci, C., Atzori, M. G., Lacal, P. M., & Graziani, G. (2020) · Cancers · doi:10.3390/cancers12113401 · Cited by 79
Krishnamoorthy, M., Lenehan, J. G., & Vareki, S. M. (2020) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaa216 · Cited by 75
The miRNAs Role in Melanoma and in Its Resistance to Therapy
Varrone, F., & Caputo, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030878 · Cited by 79
Targeted Therapy and Immunotherapy in Melanoma
Lazaroff, J. M., & Bolotin, D. (2022) · Dermatologic Clinics · doi:10.1016/j.det.2022.07.007 · Cited by 77
A user's perspective on GeoMxTM digital spatial profiling
Van, T. M., & Blank, C. U. (2019) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2019.05.001 · Cited by 76
Perspectives on the Neoadjuvant Use of Immunotherapy in Hepatocellular Carcinoma
Pinato, D. J., Fessas, P., Sapisochin, G., & Marron, T. U. (2021) · Hepatology · doi:10.1002/hep.31697 · Cited by 74
Budczies, J., Kirchner, M., Kluck, K., Kazdal, D. N., Glade, J., Allgäuer, M., Kriegsmann, M., Heußel, C. P., Herth, F. J. F., Winter, H., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2020.1860586 · Cited by 74
Vascular normalization in immunotherapy: A promising mechanisms combined with radiotherapy
Liu, Z., Zhao, Q., Zheng, Z., Liu, S., Meng, L., Dong, L., & Jiang, X. M. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111607 · Cited by 78
Kreatsoulas, D. C., Bolyard, C. M., Wu, B. X., Çam, H., Giglio, P., & Li, Z. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01298-0 · Cited by 75
Ulas, E. B., Dickhoff, C., Schneiders, F. L., Senan, S., & Bahce, I. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100244 · Cited by 73
B Cells in Patients With Melanoma: Implications for Treatment With Checkpoint Inhibitor Antibodies
Willsmore, Z. N., Harris, R. J. C., Crescioli, S., Hussein, K., Kakkassery, H., Thapa, D., Cheung, A., Chauhan, J., Bax, H. J., Chenoweth, A. M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.622442 · Cited by 72
Batf3+ DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy
Liu, J., Rozeman, E. A., O’Donnell, J. S., Allen, S. M., Fanchi, L. F., Smyth, M. J., Blank, C. U., & Teng, M. W. L. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1546068 · Cited by 71
The right Timing, right combination, right sequence, and right delivery for Cancer immunotherapy
Kwon, M., Jung, H., Nam, G., & Kim, I.-S. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.01.009 · Cited by 77
Rawson, R. V., Adhikari, C., Bierman, C., Lo, S., Shklovskaya, E., Rozeman, E. A., Menzies, A. M., van Akkooi, A. C. J., Shannon, K. F., Gonzalez, M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.03.006 · Cited by 69
Self-citationThe potential role of the microbiota in prostate cancer pathogenesis and treatment
Pernigoni, N., Guo, C. W., Gallagher, L., Yuan, W., Colucci, M., Troiani, M., Liu, L., Maraccani, L., Guccini, I., Migliorini, D., et al. (2023) · Nature Reviews Urology · doi:10.1038/s41585-023-00795-2 · Cited by 72
Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy
Wang, S. L., & Chan, T. A.-T. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.03.006 · Cited by 80
Kaseb, A. O., Vence, L. M., Blando, J. M., Yadav, S. S., Ikoma, N., Pestana, R. C., Vauthey, J., Allison, J. P., & Sharma, P. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0605 · Cited by 67
Self-citationImmune checkpoint inhibitors in melanoma in the metastatic, neoadjuvant, and adjuvant setting
Herrscher, H., & Robert, C. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000610 · Cited by 70
Immune-based therapies in penile cancer
Joshi, V. B., Spiess, P. E., Necchi, A., Pettaway, C. A., & Chahoud, J. (2022) · Nature Reviews Urology · doi:10.1038/s41585-022-00617-x · Cited by 66
Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial
Davar, D., Morrison, R. M., Dzutsev, A., Karunamurthy, A. D., Chauvin, J.-M., Amatore, F., Deutsch, J. S., das Neves, R. X., Rodrigues, R. R., McCulloch, J. A., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.10.007 · Cited by 75
Multiplex Tissue Imaging: Spatial Revelations in the Tumor Microenvironment
van Dam, S., Baars, M. J. D., & Vercoulen, Y. (2022) · Cancers · doi:10.3390/cancers14133170 · Cited by 67
Distinct tumor microenvironments of lytic and blastic bone metastases in prostate cancer patients
Ihle, C. L., Provera, M. D., Straign, D. M., Smith, E. E., Edgerton, S. M., van Bokhoven, A., Lucia, M. S., & Owens, P. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0753-3 · Cited by 66
Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?
Ahern, E. S., Solomon, B., Hui, R., Pavlakis, N., O'Byrne, K. J., & Hughes, B. G. M. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002248 · Cited by 65
Zhu, X., Li, K., & Sun, H. (2020) · Genes & Diseases · doi:10.1016/j.gendis.2020.02.002 · Cited by 63
Lü, J., Li, L., Lan, Y., Liang, Y., & Meng, H. (2019) · Cancer Medicine · doi:10.1002/cam4.2661 · Cited by 63
Farren, M. R., Sayegh, L., Ware, M. B., Chen, H.-R., Gong, J., Liang, Y., Krasinskas, A. M., Maithel, S. K., Zaidi, M. Y., Sarmiento, J. M., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.130362 · Cited by 63
Hosein, A. N., Dangol, G., Okumura, T., Roszik, J., Rajapakshe, K., Siemann, M., Zaid, M., Ghosh, B., Monberg, M., Guerrero, P. A., et al. (2022) · Gastroenterology · doi:10.1053/j.gastro.2021.12.273 · Cited by 61
Roland, C. L., Nassif, E. F., Keung, E. Z.-Y., Wang, W., Lazar, A. J., Lin, H. Y., Chelvanambi, M., Parra, E. R., Wani, K., Guadagnolo, B. A., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00726-z · Cited by 64
Self-citationVries, N. L. D., Mahfouz, A. E., Koning, F., & de Miranda, N. F. C. C. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01254 · Cited by 58
Current status and perspectives of immune checkpoint inhibitors for colorectal cancer
Hirano, H., Takashima, A., Hamaguchi, T., Shida, D., & Kanemitsu, Y. (2020) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaa200 · Cited by 63
Relatlimab: a novel drug targeting immune checkpoint LAG-3 in melanoma therapy
Su, J., Fu, Y., Cui, Z., Abıdın, Z. U., Yuan, J., Zhang, X., Li, R., & Zhao, C. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1349081 · Cited by 59
Stewart, R. L., Matynia, A. P., Factor, R. E., & Varley, K. E. (2020) · Scientific Reports · doi:10.1038/s41598-020-63539-x · Cited by 57
Biomarkers for immunotherapy for treatment of glioblastoma
Lynes, J. P., Nwankwo, A., Sur, H. P., Sanchez, V. E., Sarpong, K., Ariyo, O., Dominah, G. A., & Nduom, E. K.-E. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000348 · Cited by 60
Reijers, I. L. M., Rawson, R. V., Colebatch, A. J., Rozeman, E. A., Menzies, A., van Akkooi, A. C. J., Shannon, K. F., Wouters, M. W. J. M., Saw, R. P. M., van Houdt, W. J., et al. (2022) · JAMA Surgery · doi:10.1001/jamasurg.2021.7554 · Cited by 57
Deep learning reveals predictive sequence concepts within immune repertoires to immunotherapy
Sidhom, J.-W., Oliveira, G., Ross-MacDonald, P., Wind-Rotolo, M., Wu, C. J., Pardoll, D. M., & Baras, A. S. (2022) · Science Advances · doi:10.1126/sciadv.abq5089 · Cited by 57
Wawrzyniak, P., & Hartman, M. L. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02294-x · Cited by 62
Emerging immunotherapies for malignant glioma: from immunogenomics to cell therapy
Dunn, G. P., Cloughesy, T. F., Maus, M. V., Prins, R. M., Reardon, D. A., & Sonabend, A. M. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa154 · Cited by 56
Therapy-Induced Modulation of the Tumor Microenvironment: New Opportunities for Cancer Therapies
Benavente, S., Sánchez-García, A., Naches, S., LLeonart, M. E., & Lorente, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.582884 · Cited by 57
CXCL14 Promotes a Robust Brain Tumor-Associated Immune Response in Glioma
Kumar, A., Mohamed, E., Tong, S., Chen, K. Y., Mukherjee, J., Lim, Y., Wong, C. M., Boosalis, Z., Shai, A., Pieper, R. O., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2830 · Cited by 56
Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma
Ho, J., Mattei, J., Tetzlaff, M. T., Williams, M. D., Davies, M. A., Diab, A. K., Oliva, I. C. G., McQuade, J. L., Patel, S. P., Tawbi, H. A., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1001150 · Cited by 56
Self-citationThe promise of combining cancer vaccine and checkpoint blockade for treating HPV-related cancer
Shibata, T., Lieblong, B. J., Sasagawa, T., & Nakagawa, M. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.07.001 · Cited by 54
Moya‐Plana, A., Auperin, A., Obongo, R., Baglin, A., Ferrand, F. R., BAUJAT, B., Saroul, N., Casiraghi, O., Vergèz, S., Herman, P., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.09.007 · Cited by 58
Yang, G., Su, X., Yang, H., Luo, G., Gao, C., Zheng, Y., Xie, W., Huang, M., Bei, T., Bai, Y., et al. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-3352 · Cited by 54
Postow, M. A., Goldman, D. A., Shoushtari, A. N., Warner, A. B., Callahan, M. K., Momtaz, P., Smithy, J. W., Naito, E., Cugliari, M. K., Raber, V., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01570 · Cited by 57
Single-cell manifold-preserving feature selection for detecting rare cell populations
Liang, S., Mohanty, V., Dou, J., Miao, Q., Huang, Y., Müftüoğlu, M., Ding, L., Peng, W., & Chen, K. (2021) · Nature Computational Science · doi:10.1038/s43588-021-00070-7 · Cited by 53
WADA-OHNO, M., Ito, T., & Furue, M. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0666-x · Cited by 56
Metadata
- Authors
- Amaria, R. N., Reddy, S. M., Tawbi, H. A., Davies, M. A., Ross, M. I., Glitza, I. C., Cormier, J. N., Lewis, C., Hwu, W.-J., Hanna, E., Diab, A., Wong, M. K., Royal, R., Gross, N., Weber, R., Lai, S. Y., Ehlers, R., Blando, J., Milton, D. R., Woodman, S., Kageyama, R., Wells, D. K., Hwu, P., Patel, S. P., Lucci, A., Hessel, A., Lee, J. E., Gershenwald, J., Simpson, L., Burton, E. M., Posada, L., Haydu, L., Wang, L., Zhang, S., Lazar, A. J., Hudgens, C. W., Gopalakrishnan, V., Reuben, A., Andrews, M. C., Spencer, C. N., Prieto, V., Sharma, P., Allison, J., Tetzlaff, M. T., & Wargo, J. A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Parker Institute for Cancer Immunotherapy (US)
- Corresponding author
- Wargo, Jennifer A.
- ORCID
- Amaria, Rodabe N.
- Reddy, Sangeetha M.
- Tawbi, Hussein A.
- Davies, Michael A.
- Ross, Merrick I.
- Cormier, Janice N.
- Lewis, Carol
- Hwu, Wen-Jen
- Hanna, Ehab
- Diab, Adi
- Wong, Michael K.
- Gross, Neil
- Weber, Randal
- Lai, Stephen Y.
- Blando, Jorge
- Woodman, Scott
- Kageyama, Robin
- Wells, Daniel K.
- Hwu, Patrick
- Patel, Sapna P.
- Lucci, Anthony
- Lee, Jeffrey E.
- Gershenwald, Jeffrey
- Burton, Elizabeth M.
- Haydu, Lauren
- Wang, Linghua
- Zhang, Shaojun
- Lazar, Alexander J.
- Hudgens, Courtney W.
- Gopalakrishnan, Vancheswaran
- Reuben, Alexandre
- Andrews, Miles C.
- Spencer, Christine N.
- Prieto, Victor
- Sharma, Padmanee
- Allison, James
- Tetzlaff, Michael T.
- Wargo, Jennifer A.
- Venue
- Nature Medicine
- Published
- 2018-10-08
- Volume
- 24
- Issue
- 11
- Pages
- 1649-1654
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC6481682
- OpenAlex
- W2894584497
- Semantic Scholar
- 251ac2984307dc31d5a4596caa7a07c90195b1e8
- Cited by
- 835
- References
- 31
- Citations by year
- 2026: 49 · 2025: 80 · 2024: 102 · 2023: 116 · 2022: 119 · 2021: 130 · 2020: 142 · 2019: 79 · 2018: 12
- FWCI
- 34.49
- Type
- journal article
- Language
- en
- Update notices
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Department of Defense
- Bristol-Myers Squibb
- Nature
- National Institutes of Health (UL1TR000371)
- University of Texas MD Anderson Cancer Center
- National Cancer Institute (T32CA009666, K08CA160692)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- melanoma, nivolumab, ipilimumab, combination immunotherapy, pathological complete response, T cell infiltration, lymphocyte infiltration, treatment-related adverse events, biomarkers
- MeSH terms
- Ipilimumab, Nivolumab, Adult, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Male, Melanoma, Middle Aged, Neoplasm Staging, Risk Factors, Disease-Free Survival, Neoadjuvant Therapy, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
